EXHALE-4

A Study to Assess the Effect of Dexpramipexole in Adolescents and Adults with Eosinophilic Asthma

Study Name:
A Study to Assess the Effect of Dexpramipexole in Adolescents and Adults with Eosinophilic Asthma

Targeted Disease(s):
Asthma

Purpose of Study:

The purpose of this study, EXHALE-4, is to assess the efficacy and safety of Dexpramipexole, an oral eosinophil maturation inhibitor, in patients ≥12 years of age with inadequately controlled moderate-severe eosinophilic asthma (GINA Step 3, 4, or 5). The primary endpoint of this study is change in lung function (FEV1) from baseline.

Study Dates:
January 30, 2023 - December 30, 2024

Type of Study:
Pre-Market

Study Design:
Controlled Design

Study Location:
Nationwide

Funding Source:
Areteia Therapeutics

Contact:

EXHALE Recruiting: 888-584-9281
[email protected]

ClinicalTrails.gov Identifier:
NCT05748600

Register for Trial
Freedom From Smoking Clinic - Richmond, VA
Richmond, VA | Sep 03, 2024
COPD Educator Course
, | Oct 17, 2024